Lv61
2750 积分 2023-07-20 加入
Connecting the mechanisms of tumor sex differences with cancer therapy
11小时前
已完结
One-year remission of therapy-resistant SLE after a single course with the bispecific CD3: BCMA antibody teclistamab, but induction of a non-infectious Crohn’s-like inflammatory bowel disease
9天前
已完结
Skeletal muscle endothelial dysfunction through the activin A–PGC1α axis drives progression of cancer cachexia
27天前
已完结
A distinct priming phase regulates CD8 T cell immunity by orchestrating paracrine IL-2 signals
27天前
已完结
Skeletal muscle endothelial dysfunction through the activin A–PGC1α axis drives progression of cancer cachexia
27天前
已关闭
Low-dose cyclophosphamide combined with IL-2 inhibits tumor growth by decreasing regulatory T cells and increasing CD8+ T cells and natural killer cells in mice
27天前
已完结
The oncolytic virus VT09X optimizes immune checkpoint therapy in low immunogenic melanoma
28天前
已完结
Immunogenicity of Therapeutic Antibodies Used for Inflammatory Bowel Disease: Treatment and Clinical Considerations
1个月前
已完结
MA11.04 First-in-Class PD-1/IL-2 Bispecific Antibody IBI363 In Patients with Advanced Non-Small Cell Lung Cancer in a Phase I Study
2个月前
已完结
VP4-2024: First-in-class PD-1/IL-2 bispecific antibody fusion protein IBI363 in patients (pts) with advanced solid tumors: First-in-human phase I study
2个月前
已完结
皖公网安备34019202002308
